Purpose To evaluated the efficacy and safety of sorafenib for Chinese patients with mRCC.Methods We analyzed the clinical data from 67 patients with mRCC in our hospital.All patients were diagnosed as mRCC histopathologically and all of them were received 400mg sorafenib twice daily until PD or serious adverse events.The primary endpoint was OS and the secondary endpoint was PFS,ORR and safety.The efficacy was evaluated by the RECIST 1.1.SPSS statistical software was used to analyze the clinical data and P<0.05 was considered statistically significant.Results The median follow-up periods for 67 eligible patients were19.5 months.The median OS and PFS were 26.9 months and 14.8 months,respectively.In the analysis of curative effect,all data were collected including 3 cases with complete response(CR),18 cases with partial response(PR),33 cases with stable disease(SD)and 13 cases with progressive disease(PD).ORR for the whole group of patients was 80.6%(54/67).Otherwise,4 cases had long-term survival and the maximum survival period was over 100 months.The adverse reactions were mostly mild or moderate.The most common adverse reactions were hand-foot syndrome and fatigue.There was no 4 degree adverse reaction.Conclusion In our center,Sorafenib have good efficacy and safety for Chinese patients with mRCC.Another large-scale multicenter studies are needed to confirm this conclusion.